Chester County News and Community Website
WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) recently unveiled a draft guidance designed to enhance multiregional clinical trials (MRCTs) in oncology, aimed at improving data relevance for …
FDA Issues Draft Guidance on Multiregional Clinical Trials in Oncology Read More
BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) is set to present pivotal data from its nomlabofusp Phase 1 and Phase 2 studies at the International Congress for Ataxia Research …
Larimar Therapeutics to Present Groundbreaking Nomlabofusp Studies at ICAR Conference Read More
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has commenced its Phase 2a clinical trial for ATI-2138, an innovative oral covalent inhibitor targeting ITK and JAK3, aimed at treating moderate to …
Aclaris Therapeutics Launches Phase 2a Trial for ATI-2138 in Atopic Dermatitis Read More
PHILADELPHIA, PA — Passage Bio, Inc. has unveiled promising interim data from its ongoing global Phase 1/2 upliFT-D clinical trial at the 14th International Conference on Frontotemporal Dementias (ISFTD2024). The study …
Passage Bio Shares Promising Data on PBFT02 for Frontotemporal Dementia Read More
MALVERN, PA — Endo, Inc. (OTCQX: NDOI) has unveiled promising data from its Phase 2 clinical study of collagenase clostridium histolyticum (CCH) in treating plantar fibromatosis, presented at the American Orthopaedic …
Endo, Inc. Highlights Promising Study Results for Plantar Fibromatosis Treatment Read More
WILMINGTON, DE — Prelude Therapeutics Incorporated this week unveiled interim results from its Phase 1 trial of PRT3789, a pioneering therapy designed to target cancers with a SMARCA4 mutation. The data, …
Prelude Therapeutics Releases Promising Phase 1 Data on Novel Cancer Treatment Read More
NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) has announced encouraging interim results from its global Phase 1b FURTHER trial, presented at the prestigious IASCLC 2024 World Conference on Lung …
ArriVent BioPharma Unveils Promising Phase 1b Data for Firmonertinib in Treating NSCLC Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) has revealed groundbreaking clinical data on its novel therapeutic agent, PRT3789, at the European Society of Medical Oncology (ESMO) Congress 2024 in Barcelona. …
Prelude Therapeutics Unveils Promising Data on PRT3789 at ESMO Congress 2024 Read More
PHOENIXVILLE, PA — PleoPharma, Inc. has announced promising results from a Phase 2b study evaluating its leading drug candidate, PP-01, intended for mitigating Cannabis Withdrawal Syndrome. Conducted across 22 US addiction …
PleoPharma’s PP-01 Shows Promise in Treating Cannabis Withdrawal Syndrome Read More
KING OF PRUSSIA, PA — CluePoints has announced the full agenda and speaker lineup for the highly anticipated RBQMLive 2024. Scheduled for September 24-25, this virtual event promises an in-depth exploration …
CluePoints Unveils RBQMLive 2024 Agenda: A Pivotal Event for Clinical Trial Innovation Read More